全文获取类型
收费全文 | 62450篇 |
免费 | 4040篇 |
国内免费 | 1635篇 |
专业分类
耳鼻咽喉 | 486篇 |
儿科学 | 1028篇 |
妇产科学 | 675篇 |
基础医学 | 5297篇 |
口腔科学 | 1089篇 |
临床医学 | 5352篇 |
内科学 | 5887篇 |
皮肤病学 | 535篇 |
神经病学 | 4112篇 |
特种医学 | 1390篇 |
外国民族医学 | 6篇 |
外科学 | 5751篇 |
综合类 | 11084篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 5252篇 |
眼科学 | 4903篇 |
药学 | 5280篇 |
113篇 | |
中国医学 | 8146篇 |
肿瘤学 | 1734篇 |
出版年
2024年 | 212篇 |
2023年 | 1099篇 |
2022年 | 1924篇 |
2021年 | 2718篇 |
2020年 | 2438篇 |
2019年 | 2447篇 |
2018年 | 2221篇 |
2017年 | 2100篇 |
2016年 | 1952篇 |
2015年 | 1702篇 |
2014年 | 3868篇 |
2013年 | 3648篇 |
2012年 | 3486篇 |
2011年 | 4243篇 |
2010年 | 3857篇 |
2009年 | 2914篇 |
2008年 | 2685篇 |
2007年 | 2881篇 |
2006年 | 2718篇 |
2005年 | 2272篇 |
2004年 | 1859篇 |
2003年 | 1695篇 |
2002年 | 1218篇 |
2001年 | 1087篇 |
2000年 | 900篇 |
1999年 | 783篇 |
1998年 | 648篇 |
1997年 | 615篇 |
1996年 | 490篇 |
1995年 | 529篇 |
1994年 | 481篇 |
1993年 | 369篇 |
1992年 | 380篇 |
1991年 | 327篇 |
1990年 | 285篇 |
1989年 | 285篇 |
1988年 | 282篇 |
1987年 | 239篇 |
1986年 | 232篇 |
1985年 | 484篇 |
1984年 | 467篇 |
1983年 | 376篇 |
1982年 | 414篇 |
1981年 | 409篇 |
1980年 | 386篇 |
1979年 | 332篇 |
1978年 | 295篇 |
1977年 | 255篇 |
1976年 | 193篇 |
1974年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
2.
3.
4.
5.
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
7.
Hyperosmotic tear stimulates human corneal nerve endings, activates ocular immune response, and elicits dry-eye symptoms. A soft contact lens (SCL) covers the cornea preventing it from experiencing direct tear evaporation and the resulting blink-periodic salinity increases. For the cornea to experience hyperosmolarity due to tear evaporation, salt must transport across the SCL to the post-lens tear film (PoLTF) bathing the cornea. Consequently, limited salt transport across a SCL potentially protects the ocular surface from hyperosmotic tear. In addition, despite lens-wear discomfort sharing common sensations to dry eye, no correlation is available between measured tear hyperosmolarity and SCL-wear discomfort. Lack of documentation is likely because clinical measurements of tear osmolarity during lens wear do not interrogate the tear osmolarity of the PoLTF that actually overlays the cornea. Rather, tear osmolarity is clinically measured in the tear meniscus. For the first time, we mathematically quantify tear osmolarity in the PoLTF and show that it differs significantly from the clinically measured tear-meniscus osmolarity. We show further that aqueous-deficient dry eye and evaporative dry eye both exacerbate the hyperosmolarity of the PoLTF. Nevertheless, depending on lens salt-transport properties (i.e., diffusivity, partition coefficient, and thickness), a SCL can indeed protect against corneal hyperosmolarity by reducing PoLTF salinity to below that of the ocular surface during no-lens wear. Importantly, PoLTF osmolarity for dry-eye patients can be reduced to that of normal eyes with no-lens wear provided that the lens exhibits a low lens-salt diffusivity. Infrequent blinking increases PoLTF osmolarity consistent with lens-wear discomfort. Judicious design of SCL material salt-transport properties can ameliorate corneal hyperosmolarity. Our results confirm the importance of PoLTF osmolarity during SCL wear and indicate a possible relation between PoLTF osmolarity and contact-lens discomfort. 相似文献
8.
Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface. 相似文献
9.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
10.